Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
ARQTArcutis Biotherapeutics(ARQT) Seeking Alpha·2024-08-23 05:13
FocalFinder/iStock via Getty Images Investment Overview At the end of January this year, I shared a note on Seeking Alpha covering Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). This is a Westlake Village, California-based biotech that markets and sells two dermatological products — ZORYVE® (roflumilast) cream 0.3%, and ZORYVE® (roflumilast) topical foam 0.3%. Roflumilast is — according to Arcutis' Q2 2024 quarterly report / 10Q submission: a highly potent and selective phosphodiesterase-4 ("PDE4") inhibi ...